Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

By C. Wanner, V. Krane, Winfried März, M. Olschewski, J. Mann, G. Ruf, E. Ritz. New England Journal of Medicine, 2005

2,621 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. (2008, result): “However, not all recent evidence is onsistent with this premise: atorvastatin did not signifiantly reduce the primary end point of cardiovascular death, onfatal MI, or stroke in a prospective randomized trial of atients with diabetes and end-stage CKD who were ndergoing hemodialysis (69).”
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “trolled trials have consistently shown no survival benefit from multiple new treatment strategies, such as increased dialysis dose (2,3), intensified nutrition (4), homocysteine-lowering therapy (5), normalization of hemoglobin with erythropoietin (6,7), lipid lowering with statins (8), and treatmen”